



# Practical Strategies to Reduce Risk for Drug-Device Combination Products

**Workshop | April 13–15, 2021**

***Agenda at a Glance***

[REGISTER HERE](#)

This free 3-day virtual workshop (4 hours per day) brings together industry experts and thought leaders in a unique forum to address a series of challenges and practical strategies to de-risk their Injectable Combination Product development and commercialization.

## **Key Challenges & Risks to be addressed are:**

- Translation of regulation to development execution
- Drug & Device Integration
- Device reliability & robustness
- Change & Lifecycle management

## **Learning Objectives:**

- Understand latest regulatory expectations including understanding risk
- Understand clinical, human factors and usability considerations
- Learn strategies to de-risk the combination product development process and use testing to inform it
- Lifecycle management considerations

Featuring  
Industry Experts  
from Sanofi,  
Eli Lilly and Co.,  
Amgen and  
More!

***A Certificate of Completion will be provided to all attendees that join all 3 days of the event.***





Tuesday  
April 13, 2021

**The New Landscape:**  
Changing Regulatory  
and Patient Needs

10:00 AM	<b>Welcome</b> <i>Erin O'Brien Vice President, Integrated Marketing, West</i>
10:10 AM	<b>Dynamic Regulatory Environment of Drug-Device Combination Products</b> <i>Diane Paskiet Director of Scientific Affairs, West</i>
10:45 AM	<b>Combination Products Dictionary and Thesaurus</b> <i>Susan Neadle MS, BS, FAAO, DEx &amp; PE BB, Executive Director, Combination Products &amp; Medical Devices Regulatory Affairs, Amgen</i>
11:00 AM	<b>Combination Products Risk Management</b> <i>Susan Neadle MS, BS, FAAO, DEx &amp; PE BB, Executive Director, Combination Products &amp; Medical Devices Regulatory Affairs, Amgen</i>
11:30 AM	<b>Q&amp;A</b>
11:45 AM	<b>Break</b>
12:15 PM	<b>Biologics Combination Products Necessitate Integrated Development Combining Molecule, Formulation, Process and Device Design</b> <i>Atul Saluja Senior Director and Head, Biologics Drug Product Development US, Sanofi</i>
12:45 PM	<b>From Discovery to Lifecycle Management – Developability Assessment and Device Feasibility</b> <i>Atul Patel Vice President, Devices and Delivery Systems, West</i>
1:15 PM	<b>Considerations for Clinical Outcomes of Combination Products</b> <i>Allison Radwick R.Ph., Ph.D., Manager, Scientific Affairs, West</i>
1:45 PM	<b>Q&amp;A</b>



Wednesday  
April 14, 2021

**Technical Strategy:**  
Development  
Considerations for  
Combination Products

10:00 AM	<b>Welcome</b> <b>Erin O'Brien</b> <i>Vice President, Integrated Marketing, West</i>
10:05 AM	<b>The Importance of Human Centered Approach to Product Development</b> <b>Binita Bhattacharya</b> <i>Manager, User Response and Patient Experience, West</i>
10:30 AM	<b>A Risk-based Approach to the Development of an Injectable Combination Product</b> <b>Fran DeGrazio</b> <i>Chief Scientific Officer, West</i>
11:00 AM	<b>Analytical Considerations for Combination Products</b> <b>Jennifer Riter</b> <i>Senior Director, Business and Technical Operations, Services and Solutions, West</i>
11:30 AM	<b>Q&amp;A</b>
11:45 AM	<b>Break</b>
12:15 PM	<b>Biological Evaluation of Drug-device Combination Products</b> <b>Cheryl Stults</b> <i>Principal at C &amp; M Technical Consulting, LLC</i>
12:45 PM	<b>Extractables and Leachables Approach to Combination Products</b> <b>Doug Kiehl</b> <i>Research Advisor, Eli Lilly and Co.</i>
1:15 PM	<b>Combination Product Functional Suitability Assessments</b> <b>Daniel Bantz</b> <i>Manager, Scientific Communications, Self-Injection Systems, West</i>
1:45 PM	<b>Q&amp;A</b>



Thursday  
April 15, 2021

**Sustaining Success:**  
Effective Planning and  
Lifecycle Management  
for Combination  
Products

10:00 AM	<b>Welcome</b> <i>Erin O'Brien Vice President, Integrated Marketing, West</i>
10:05 AM	<b>Technical and Regulatory Aspects of Pharmaceutical Product Lifecycle Management: ICH Q12</b> <i>Moheb Nasr Principal, ICH Q12 Rapporteur Nasr Pharma Regulatory Consulting</i>
10:30 AM	<b>PMSR Readiness</b> <i>Khaudeja Bano, MD VExecutive Medical Director, Combination Product Safety Head, Amgen</i>
11:00 AM	<b>Purchasing Controls: An Important Part of cGMPs</b> <i>Fran DeGrazio Chief Scientific Officer, West</i>
11:30 AM	<b>Q&amp;A</b>
11:45 AM	<b>Break</b>
12:30 PM	<b>A Platform Approach to Combination Products</b> <i>Megan Doyle Director, Global Regulatory and R&amp;D Policy, Amgen</i>
1:00 PM	<b>QMS and RMS Expectations on Combination Product Life Cycle</b> <i>Kim Trautman, Executive Vice President Medical Device International Services, NSF Medical Devices</i>
1:30 PM	<b>Q&amp;A</b>
1:45 PM	<b>Event summary and wrap up</b>